NEW YORK (GenomeWeb) – Fabric Genomics and Toma Biosciences announced today that they have partnered to codevelop an oncology genomic testing and clinical interpretation service for clinical laboratory customers.
"The goal of the collaboration is to provide labs offering cancer testing with a breakthrough assay for comprehensive analysis of all types of tumor samples, even those with limited volume and poor quality including FFPE tissue," Fabric CEO Matt Tindall said in a statement. "Our raw data-to-report platform for next-generation sequencing data analysis coupled with the Toma OS-Seq assay creates a seamless tumor profiling system for detection and clinical interpretation of somatic cancer variants."
Toma President and CEO Wolfgang Daum added that the companies' planned offering will combine Toma's wet lab and somatic bioinformatics pipeline with Fabric's annotation and reporting platform, offering labs "everything they need to conduct tumor profiling from tumor DNA to report, and can be up and running and ready to begin validation in under a week."
Specific terms of the partnership were not disclosed.